Last reviewed · How we verify
SHR-9839 ； pemetrexed ；carboplatin
At a glance
| Generic name | SHR-9839 ； pemetrexed ；carboplatin |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (PHASE1, PHASE2)
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: